提高检测灵敏度：优化用于监测依艾托考格α的贝塞斯达检测法。 - Suppr

Turning up the heat: optimizing Bethesda assays for efanesoctocog alfa monitoring.

作者信息

Herb Agathe, Wimmer Jordan, Desprez Dominique, Feugeas Olivier, Mauvieux Laurent, Sattler Laurent

机构信息

Laboratoire d'Hématologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

Centre Régional de Compétences des Maladies Hémorragiques Constitutionnelles, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

出版信息

Res Pract Thromb Haemost. 2025 Aug 5;9(6):102992. doi: 10.1016/j.rpth.2025.102992. eCollection 2025 Aug.

DOI:10.1016/j.rpth.2025.102992

PMID:40894957

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12397855/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e42/12397855/eacd2df169c4/gr1.jpg

相似文献

Turning up the heat: optimizing Bethesda assays for efanesoctocog alfa monitoring.

Res Pract Thromb Haemost. 2025 Aug 5;9(6):102992. doi: 10.1016/j.rpth.2025.102992. eCollection 2025 Aug.

Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A.

N Engl J Med. 2024 Jul 18;391(3):235-246. doi: 10.1056/NEJMoa2312611.

Efanesoctocog Alfa versus Standard and Extended Half-Life Factor VIII Prophylaxis in Adolescent and Adult Patients with Haemophilia A without Inhibitors.

Adv Ther. 2025 Jan;42(1):427-441. doi: 10.1007/s12325-024-03032-3. Epub 2024 Nov 22.

Post hoc analysis of bleeding episodes and clinically relevant pharmacokinetic parameters among children <12 years old with severe hemophilia A receiving once-weekly efanesoctocog alfa prophylaxis in the XTEND-Kids phase 3 multinational trial.

J Thromb Haemost. 2025 Jul 21. doi: 10.1016/j.jtha.2025.07.011.

Comparative Effectiveness of Valoctocogene Roxaparvovec and Efanesoctocog Alfa in the Treatment of Severe Hemophilia A: A Matching-Adjusted Indirect Comparison of Bleeding Frequency.

Adv Ther. 2025 Sep 9. doi: 10.1007/s12325-025-03339-9.

A phase 1, open-label study to assess the pharmacokinetics, safety, and tolerability of a single intravenous injection of efanesoctocog alfa in adults with type 2N or type 3 von Willebrand disease.

J Thromb Haemost. 2025 Jul 18. doi: 10.1016/j.jtha.2025.07.013.

Efanesoctocog Alfa Population Pharmacokinetics and Repeated Time-To-Event Analysis of Bleeds in Adults, Adolescents, and Children with Severe Hemophilia A.

J Clin Pharmacol. 2025 Jul;65(7):860-872. doi: 10.1002/jcph.70008. Epub 2025 Mar 23.

A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratories.

Haemophilia. 2024 Jan;30(1):214-223. doi: 10.1111/hae.14831. Epub 2023 Oct 30.

Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa.

Res Pract Thromb Haemost. 2023 May 13;7(4):100176. doi: 10.1016/j.rpth.2023.100176. eCollection 2023 May.

Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII.

J Thromb Haemost. 2022 Jul;20(7):1674-1683. doi: 10.1111/jth.15741. Epub 2022 May 22.

本文引用的文献

A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratories.

Haemophilia. 2024 Jan;30(1):214-223. doi: 10.1111/hae.14831. Epub 2023 Oct 30.

International Council for Standardization in Haematology recommendations for laboratory measurement of factor VIII and FIX type I inhibitors.

Int J Lab Hematol. 2023 Aug;45(4):413-424. doi: 10.1111/ijlh.14109. Epub 2023 Jun 7.

Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A.

N Engl J Med. 2023 Jan 26;388(4):310-318. doi: 10.1056/NEJMoa2209226.

WFH Guidelines for the Management of Hemophilia, 3rd edition.

Haemophilia. 2020 Aug;26 Suppl 6:1-158. doi: 10.1111/hae.14046. Epub 2020 Aug 3.

BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice.

Blood. 2020 Apr 23;135(17):1484-1496. doi: 10.1182/blood.2019001292.

Evaluation of pre-analytic heat treatment protocol used in the CDC Nijmegen-Bethesda assay for heat inactivation of extended half-life haemophilia treatment products.

Haemophilia. 2020 Jan;26(1):e28-e30. doi: 10.1111/hae.13901. Epub 2019 Dec 6.

Heat inactivation of extended half-life factor VIII concentrates.

Haemophilia. 2019 Mar;25(2):e130-e131. doi: 10.1111/hae.13700. Epub 2019 Feb 12.

Effects of pre-analytical heat treatment in factor VIII (FVIII) inhibitor assays on FVIII antibody levels.

Haemophilia. 2018 May;24(3):487-491. doi: 10.1111/hae.13435. Epub 2018 Feb 20.

Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review.

Haemophilia. 2018 Mar;24(2):186-197. doi: 10.1111/hae.13424. Epub 2018 Feb 15.

Pre-analytical heat treatment and a FVIII ELISA improve Factor VIII antibody detection in acquired haemophilia A.

Br J Haematol. 2014 Sep;166(6):953-6. doi: 10.1111/bjh.12923. Epub 2014 May 9.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Turning up the heat: optimizing Bethesda assays for efanesoctocog alfa monitoring.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献